HIV and AIDS Trial, Recruiting (NCT06441123)

HIV and AIDS Trial, Recruiting NCT06441123 Sponsor: University Hospital, Montpellier Condition: HIV and AIDS

Printed from Voxsanity (voxsanity.com.au) — NCT06441123 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hiv Aids

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who are HIV-positive
People who are currently taking antiretroviral therapy (HIV medication)
People whose HIV viral load has been undetectable for more than 12 months
People whose lowest-ever CD4 immune cell count (a measure of immune system health) was below 200 cells per microlitre of blood

Who may not be able to join:

People who are not currently taking antiretroviral therapy (HIV medication)
People who are taking medications that suppress the immune system
People who have had a cancer diagnosis within the last 5 years
People who are pregnant or breastfeeding
People who are under legal guardianship, have a court-appointed curator, or are otherwise under court protection
People who are currently enrolled in another research study that has an active exclusion period
People who do not wish to take part in research
People who are not enrolled in, or do not benefit from, a social security scheme (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 04 67 33 83 40

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06441123

Sponsor: University Hospital, Montpellier

Phase: Not Applicable

Status: Recruiting

Condition: HIV and AIDS

Trial contact: 04 67 33 83 40

More information: https://clinicaltrials.gov/study/NCT06441123

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who are HIV-positive
People who are currently taking antiretroviral therapy (HIV medication)
People whose HIV viral load has been undetectable for more than 12 months
People whose lowest-ever CD4 immune cell count (a measure of immune system health) was below 200 cells per microlitre of blood

Who may not be able to join:

People who are not currently taking antiretroviral therapy (HIV medication)
People who are taking medications that suppress the immune system
People who have had a cancer diagnosis within the last 5 years
People who are pregnant or breastfeeding
People who are under legal guardianship, have a court-appointed curator, or are otherwise under court protection
People who are currently enrolled in another research study that has an active exclusion period
People who do not wish to take part in research
People who are not enrolled in, or do not benefit from, a social security scheme (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Montpellier

Registry

ClinicalTrials.gov

Start date

10 February 2025

Est. completion

10 February 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Quantity of p24 in the cell supernatant 18-20 hours after the addition of the LRAs (Latency Reversing Agents)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov